King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations
King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations
KFSH&RC CEO at GCC Harvard 1
KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending ValueDr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges
Biologics Symposium
Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
May 09, 2024 09:00 ET | Curia Global, Inc.
The symposium, Unlocking High-Throughput Biology in Drug Discovery, will take place on May 31 in Seattle and feature industry-leading scientists.
ADCT_4C_TM-R .png
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
May 09, 2024 07:15 ET | ADC Therapeutics SA
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024...
cmi_logo.png
[Latest] Global Ultrapure Water Market Size/Share Worth USD 3,989 Million by 2033 at a 10.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 02, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Ultrapure Water Market Size, Trends and Insights By Application (Cleaning,...
YSEOP_LOGO_FINAL-PURPLE-_-YELLOW (1).png
With Support from AWS, Yseop Develops a Unique Generative AI Application for Regulatory Document Generation Across BioPharma
May 02, 2024 09:00 ET | Yseop
Yseop, with support from Amazon Web Services (AWS), announced the development of an enhanced Generative AI application for the Biopharma industry.
YPrime CNS Survey - Key eCOA Attributes
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET | Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
Picture1.png
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting
April 30, 2024 08:00 ET | Eagle Pharmaceuticals, Inc.
WOODCLIFF LAKE, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will deliver a Trial in Progress presentation...
Replay_Logo_Black_CMYK.png
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
April 30, 2024 07:00 ET | Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies Phase 1/2...
23andMe_Logo_grey.png
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 16:05 ET | 23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two...